Do we really have good evidence for inadequate ATP generation in ME/CFS?
Unable to link specific studies now as I don’t have my laptop today and am on my phone, but you’re right that it’s inconsistent across studies. For me, despite individual inconsistencies in studies, I see a strong global pattern pointing specifically to impairment of OxPhos and concurrent upregulation of glycolysis, glutamine metabolism, and beta oxidation as compensatory mechanisms. The upregulation of compensatory mechanisms could explain the appearance of normal function in short instances, but overall failure to maintain endurance over longer periods of time as well as deficiencies in tissues that preferentially use OxPhos under certain conditions (skeletal muscle, heart, certain parts of the brain) or that rely on OxPhos for phenotypic regulation (e.g. macrophages).
Off the top of my head we have @DMissa’s study showing reduced complex V activity in immortalized lymphoblasts, Booth et al., Lawson et al. (and at least one other study that escapes me) showing upregulated baseline ATP production from glycolysis, and several metabolomic studies showing differences in beta oxidation, glutamine and urea cycle metabolites (please correct if I’m misremembering any details since I don’t have all the papers in front of me). Furthermore, you have evidence of reduced steroid synthesis in androgenic steroids, progestins, corticosteroids, and bile acids (Germain et al. and my recent LC study Gabernet et al.), which are all dependent on conversions of cholesterol by mitochondrial NADPH-dependent enzymes. To me, this points to redox imbalance in adrenals, gonads, and liver at the very least, and is exactly what you would expect as a downstream, long-term byproduct of impaired OxPhos. You also have potential signs of redox imbalance in sphingolipid abnormalities (which has shown up as both upregulated and downregulated but strongly in either case—would have to be explained in terms of differential use of serine metabolism as a compensatory redox regulator) and the frequency of alcohol intolerance in ME/CFS (ethanol breakdown requires cytosolic reducing agents).
Granted, some of these findings could be only specific to the cell types studied. And, in the case of Lawson et al. I strongly suspect there is something in the cell preparation that actually lead to normal mitochondrial function in their PBMCs. In terms of the plasma metabolomics studies, it is unlikely to just be one pathogenic celltype that is driving those metabolic signatures, pointing to a more global deficit.
Obviously this is only speculation at this point and would need to be investigated in more detail. I’m currently working on doing exactly that. As it stands, I completely acknowledge that the exact evidence is inconsistent, though I think there is merit in the fact that several different findings across studies can all be linked by a singular mechanism.